AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011
AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.
Read more on News-Medical-Net
Comments are closed.